medgenics inc - unrestricted (MDGN) Key Developments
Medgenics Seeks Acquisitions
Nov 25 14
Medgenics, Inc. (AMEX:MDGN) has completed a Follow-on Equity Offering in the amount of $21.01 million. Medgenics said, "We intend to use the net proceeds from this offering for product development activities, including clinical trials for our most advanced product candidates and investigation of new applications for our technologies; for patent maintenance fees and intellectual property support; for licensing and research collaborations, including the research collaboration with the Children’s Hospital of Philadelphia; and for general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses."
Medgenics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 12:00 PM
Nov 24 14
Medgenics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 12:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Michael F. Cola, Chief Executive Officer, President and Director.
Medgenics Signs Research Collaboration with The Children's Hospital of Philadelphia
Nov 14 14
Medgenics has entered into a research collaboration with The Children's Hospital of Philadelphia. The partnership is aimed at paediatric rare and orphan genetic diseases and at accelerating the development of transformational new therapies for these underserved patients. The biobank at Children's Hospital of Philadelphia's Center for Applied Genomics has the larger biorepositories of paediatric genetic data in the world. Access to the genetic information in the CAG biobank is intended to enable researchers at both firms to work rapidly and efficiently to identify new rare and orphan disease targets and accelerate the development of novel therapies into clinical stage programs. Under the contract, Medgenics will pay USD 5 million to The Children's Hospital of Philadelphia and will also have a license to use the rare and orphan disease samples at the CAG biobank for the purpose of developing and commercialising therapeutic treatments and diagnostic targets for rare and orphan diseases.
Medgenics, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Oct 15 14
Medgenics, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss of $3,870,000 compared to $4,904,000 a year ago. Loss before taxes on income was $3,038,000 compared to $6,143,000 a year ago. Loss was $3,040,000 compared to $6,143,000 a year ago. Diluted loss per share was $0.21 compared to $0.33 a year ago.
For the nine months, the company reported operating loss of $12,742,000 compared to $11,924,000 a year ago. Loss before taxes on income was $12,229,000 compared to $11,916,000 a year ago. Loss was $12,237,000 compared to $11,921,000 a year ago. Diluted loss per share was $0.68 compared to $0.68 a year ago.
Medgenics, Inc. to Present Initial Clinical Data from MDGN-201 Study at European Society of Gene and Cell Therapy Congress
Oct 7 14
Medgenics, Inc. announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201, formerly known as EPODURE, will be presented at the 22nd Annual Congress of the European Society of Gene and Cell Therapy being held in The Hague, Netherlands from October 23, 2014 to October 26, 2014. The presentation entitled Prolonged Secretion of Physiological Levels of Autologous EPO by TARGT, will be presented by Dr. Garry Neil, Chief Scientific Officer. Dr. Neil will present data on the first three erythropoietin (EPO)-dependent patients from the ongoing clinical study of the TARGTsystem in dialysis patients with anemia due to end-stage renal disease or chronic kidney disease.